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SUMMARY
CCR7 is implicated in lymph node metastasis of cancer, but its role is obscure. We report a mecha-
nism explaining how interstitial flow caused by lymphatic drainage directs tumor cell migration by
autocrine CCR7 signaling. Under static conditions, lymphatic endothelium inducedCCR7-dependent
chemotaxis of tumor cells through 3Dmatrices. However, interstitial flow induced strong increases in
tumor cell migration that were also CCR7 dependent, but lymphatic independent. This autologous
chemotaxis correlatedwithmetastatic potential in four cell lines andwas verified by visualizing direc-
tional polarization of cells in the flow direction. Computational modeling revealed that transcellular
gradients of CCR7 ligand were created under flow to drive this response. This illustrates how tumor
cells may be guided to lymphatics during metastasis.INTRODUCTION
Although lymphatic metastasis is the major route of
dissemination for many cancers (Chambers et al., 2002;
Nathanson, 2003), the mechanisms underlying metastasis
are unclear. It is suggested that more aggressive tumors
induce lymphangiogenesis via secretion of lymphangio-
genic growth factors (He et al., 2005; Mandriota et al.,
2001; Skobe et al., 2001; Stacker et al., 2001), although
evidence for tumor lymphangiogenesis, or the necessity
of lymphangiogenesis for lymphatic metastasis, in human
cancer remains controversial (Clarijs et al., 2001; Sipos
et al., 2005; Williams et al., 2003; Wong et al., 2005).
Consistently, however, the occurrence of lymph node
metastasis has been linked with expression of chemokine
receptors, particularly CCR7 and CXCR4 (Arya et al.,
2004; Darash-Yahana et al., 2004; Muller et al., 2001;
Takeuchi et al., 2004). CCR7 is of particular interest since526 Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc.memory CD4+ T cells and dendritic cells, which constitu-
tively traffic through lymphatics, require CCR7 for migra-
tion to lymph nodes (Debes et al., 2005; Forster et al.,
1999; Ohl et al., 2004; Randolph et al., 2005). Cancer cells
may exploit similar mechanisms to access the lymphatics:
indeed, the incidence of lymph node metastases has been
correlated with the presence of CCR7 on tissue sections
of human cancers including breast cancer (Cabioglu
et al., 2005) and melanoma (Takeuchi et al., 2004; Wiley
et al., 2001) as well as colorectal (Gunther et al., 2005),
head and neck (Wang et al., 2005), prostate (Heresi
et al., 2005), non-small lung (Takanami, 2003), esophageal
squamous cell (Ding et al., 2003), and gastric (Mashino
et al., 2002) cancers. The known ligands for CCR7 are
CCL21 and CCL19. CCL21 is expressed by lymphatic
vessels (Gunn et al., 1998) and is secreted as a 12 kDa
protein but is readily immobilized within extracellular
matrix (ECM) by binding to sulfated proteoglycans (PatelSIGNIFICANCE
Many cancers spread via the lymphatics, but the mechanisms used by tumor cells to access lymphatics remain
unclear, although expression of the chemokine receptor CCR7 has been correlated with lymph node metastasis.
We provide evidence that physiological levels of interstitial flow strongly enhance tumor cell polarization and mi-
gration. We show how tumor cells utilize interstitial flow to create and amplify autologous transcellular chemokine
gradients and thus chemotact toward the draining lymphatic even when too far to sense any putative chemotactic
signals from the lymphatic. This work also provides a twist to the well-described phenomenon of chemotaxis by
showing that a cell can receive directional cues while at the same time being the source of such cues.
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Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 1. 3D Tissue Culture Model of the Tumor-Lymphatic
Microenvironment
(A) Schematic of the tumor microenvironment where lymphatic vessels
drain interstitial fluid, creating flow directed toward the lymphatic. This
fluid convection promotes transport of signals from tumor to lymphatic
but counteracts diffusive transport of signals from lymphatic to tumor,
such as the lymphocyte homing chemokine CCL21. The potential role
of CCR7-mediated autologous chemotaxis in this process is investi-
gated here along with paracrine CCR7 signaling by lymphatics.
(B) Schematic of tissue culture model system incorporating a 3D extra-
cellular matrix and interstitial flow to examine crosstalk between tumor
cells and lymphatic endothelial cells (LECs) as well as the effects of
flow on tumor cell migration, with and without LECs. Inset: Histological
cross-section showing interface of tumor suspension, porous mem-
brane, and LECs (arrowheads). Arrows indicate transmigrating tumor
cells in membrane pores.et al., 2001). Similarly, CCL19 is secreted as an 8.8 kDa
protein and is required for immunological functions
including T cell priming and dendrite production by
antigen-presenting cells, thereby affecting migratory
properties (Randolph et al., 2005).
We suggest here a mechanism for CCR7-mediated
tumor cell chemotaxis to lymphatics. In addition to sens-
ing chemotactic gradients of CCL21/19 from lymphatics,
we show that tumor cells also generate autologous gradi-
ents of CCR7 ligands by secreting them into the ECM
under the influence of slow interstitial flow (IF). This mech-
anism uses the drainage function of lymphatics to direct
tumor cells in a chemotactic manner toward lymphatic
vessels serving the tumor, thus promoting tumor cell
migration toward functional more than nonfunctional
lymphatics. Furthermore, it is well established that tumors
are highly vascularized and contain abnormally leaky
capillaries (Jain, 2003, 2005; Carmeliet, 2003); tumor fluid
flows through the interstitial space toward the draining
lymphatics with a velocity of 0.1–0.8 mm/s (Chary and
Jain, 1989; Dafni et al., 2002). This proposed mechanism
follows from our recent computational demonstration
that transcellular gradients of autocrine-secreted morpho-
gen can form under IF (Fleury et al., 2006; Helm et al.,
2005) in a 3D environment. The microenvironment created
by normal lymphatic functioning in the space between the
tumor margin and lymphatic vessel may similarly facilitate
tumor migration toward lymphatics (Figure 1A).
We developed a simple in vitro 3D culture model to
mimic this biophysical microenvironment and explore
the interplay of IF and chemokine signaling between tumor
cells and lymphatic endothelial cells (LECs; Figure 1B).
Matrigel, a reconstituted ECM that is rich in sulfated
proteoglycans (Kleinman and Martin, 2005), was used to
facilitate chemokine interactions with the ECM and allow
pericellular gradients of both tumor-secreted and LEC-
secreted CCL21 to be established as they would in vivo.
We show, using four different human cell lines (three
breast and one melanoma), that tumor cells can create
autocrine gradients of CCR7 ligands that guide their che-
motaxis in the direction of flow (i.e., toward functional
lymphatics). This occurs when a physiologic level of IF is
present, even if LECs are absent, although the effect is
greatly amplified when both IF and LECs are present.
These findings introduce the mechanism of ‘‘autologous
chemotaxis’’ for guiding tumor cells toward functional
lymphatics and give mechanistic insight into why tumor
CCR7 expression is correlated to lymph node metastasis.
They suggest that CCR7 ligand secretion by tumor cells
themselves, rather than or in addition to secretion by
lymphatics, may be a potential target for preventing
metastatic spread.
(C) Confocal image of the underside of the transwell membrane show-
ing the lymphatic endothelial cell monolayer (CD31, red), one adhering
tumor cell (GFP, green, arrowhead), and one tumor cell in the process
of transmigration through a pore (arrow). Nuclei are shown in blue.
Scale bar, 20 mm.
(D) Human dermal microvascular LECs as characterized by immuno-
fluorescence for indicated markers. Scale bars, 100 mm.
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Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 2. Tumor Cells Express Functional CCR7
(A) Immunofluorescence demonstrates CCR7 receptor expression in the three tumor cell lines, but very little in LECs or the nontumorigenic cell line
MCF10A. Scale bar, 50 mm.
(B) Representative PCR (top) and Western blot (bottom) analysis again demonstrates CCR7 expression in tumor cells but not LECs or the nontumori-
genic MCF10A.
(C) CCR7 band intensities from densitometry of Western blots (n = 3), normalized to expression in MDA cells.
(D–F) CCR7 expression (brown) in human breast tissue samples. Very low levels of CCR7 were detected in normal epithelial ductal tissue (D), while
ductal carcinoma in situ (E) and invasive carcinoma (F) showed higher levels of CCR7 signal (tumor cells indicated by ‘‘t’’). Scale bar, 50 mm.
(G) 3D chemoinvasion up a 4 ng/ml/mm CCL21 gradient of the four cell lines tested. MCF10A cells displayed a small but insignificant response to the
CCL21 gradient, while the more invasive cell lines (ZR75-1 and MDA-MB-435S) showed substantial chemotaxis that could be abolished with
neutralizing antibodies against CCL21 and CCR7 (*p < 0.05, **p < 0.01 compared with control [random migration in basal medium]; Dp < 0.05,
DDp < 0.01 between other groups as indicated). Error bars represent mean ± SD.RESULTS
Tumor Cell Expression of Functional CCR7
We examined a panel of four cell lines for the presence and
functional response of CCR7, which included one nontu-
morigenic breast cell line, MCF10A (Soule et al., 1990),
two breast tumor cell lines, MCF7 (Soule et al., 1990)
and ZR75-1 (Engel et al., 1978), and one cell line of mela-
noma origin, MDA-MB-435S (Cailleau et al., 1978), which
have low, moderate, and high metastatic potential,
respectively. (We note that the MDA-MB-435S cell line
was first characterized as a breast tumor cell line
but was recently discovered to have melanoma origins
[Rae et al., 2004, 2006; http://dtp.nci.nih.gov/docs/misc/
common_files/mda-mb-435-update.html].) Immunofluo-
528 Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc.rescence (Figure 2A) demonstrated strong CCR7 expres-
sion in the three tumor cell lines but weak staining in LECs
and MCF10A cells; this was confirmed by Western blot
and PCR (Figures 2B and 2C). Human breast cancer sec-
tions were consistent with the cell line expression: low
levels of CCR7 were detected in normal breast ductal tis-
sue (Figure 2D), while strong staining was observed in
ductal carcinoma in situ (DCIS; Figure 2E) and invasive
carcinoma (Figure 2F).
Furthermore, the three tumor cell lines, but not the be-
nign cells, showed strong chemotactic invasive response
to an applied CCL21 gradient (4 ng/ml/mm) in 3D matrices,
a response that could be blocked by co neutralization of
CCL21 and CCR7 (Figure 2G). Thus, tumor cell CCR7 was
functional in driving a chemotactic response to CCL21.
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Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 3. Autocrine Secretion of CCR7 Ligands by Tumor Cells Higher in 3D versus 2D Culture
(A) Immunostaining for CCL21 and CCL19 (green) after 24 hr culture in 2D (scale bars, 25 mm) versus a 3D Matrigel matrix (scale bars, 50 mm). No
CCL19 was detected in 2D culture for any cell line, consistent with ELISA results (data not shown). Nuclei are shown in blue.
(B–E) Human tissue samples were also stained for CCL21 to confirm autocrine ligand production in vivo. (B) Very low levels of CCL21 were detected in
normal breast ductal tissue. (C) CCL21 was consistently detected in carcinoma in situ (brown staining, ‘‘t’’), in invasive ductal carcinoma cells (D), and
also in surrounding lymphatic vessel endothelial cells (arrowheads). (E) CCL21-positive tumor cells (arrows) were observed within a similarly CCL21-
positive peritumoral invasive ductal carcinoma lymphatic vessel (arrowhead). Scale bars, 50 mm.
(F) Comparison of total CCR7 ligand secreted by cells in 2D versus 3D culture by ELISA demonstrates substantially higher secretion rates of CCL21
and CCL19 in 3D culture for all cell lines tested, indicating the importance of microenvironment on chemokine signaling between tumor cells and
lymphatics. Error bars represent mean ± SD.Autocrine Secretion of CCR7 Ligands by Tumor Cells
Although it was no surprise to find CCR7 on metastatic
tumor cells, as has previously been demonstrated, we
also observed autocrine secretion of CCR7 ligands CCL19
and CCL21 (Figures 3A–3F). The more highly invasive cell
lines (MDA-MB-435S and ZR75-1) secreted more CCR7
ligands than the MCF7 cells, MCF10A cells, or LECs. Of
note, tumor cell secretion of both CCL19 and CCL21
was significantly higher in 3D than 2D culture conditions
(Figures 3A and 3F), and CCL19 was not detected in 2D
cultured cells (Figure 3A). In 3D, the bound protein fraction
was higher than the soluble fraction (data not shown) as
would be expected due to their known matrix binding
properties (Patel et al., 2001). These observations em-
phasize the importance of the microenvironment when
studying tumor cell behavior, particularly with regards tochemokine signaling as well as indicating a role for auto-
crine CCR7 signaling in tumor cells.
Consistent with these in vitro results, we observed
CCL21 in human breast cancer tissue, with higher expres-
sion seen in DCIS and invasive carcinoma compared to
normal tissue (Figures 3B and 3D). Peritumoral lymphatics
were also CCL21 positive (Figure 3C, arrowhead), and
CCL21-expressing tumor cells could be found within a
CCL21-positive lymphatic vessel (Figure 3E), corroborat-
ing that in an in vivo setting the tumor cells secrete CCL21
as well as the lymphatics.
Paracrine Effects: CCR7-Mediated Tumor Cell
Chemotaxis toward LECs
First, to determine whether tumor cells migrate toward
lymphatics via CCR7 signaling as would be expected,Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc. 529
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Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 4. Tumor Cell Chemotaxis toward LECs Is CCR7 Mediated
Chemotaxis through a 3D matrix of each cell type toward LECs, with and without CCR7-blocking antibody cocktail (LEC and LEC block), as compared
to basal conditions (no LEC) with or without blocking antibody (conditions illustrated in schematics). MCF10A cells, which showed little CCR7 expres-
sion, were mildly chemotactic toward LECs, although in a CCR7-independent manner. MCF7, which showed higher CCR7 expression than MCF10A
but responded weakly to an imposed CCL21 gradient, also showed a small but statistically insignificant 3D chemotaxis toward LECs. Both ZR75-1
and MDA-MB-435S cells were strongly chemoattracted to LECs (*p < 0.05 compared with no LEC basal conditions; Dp < 0.05 between other groups
as indicated, and their chemotaxis was blocked with anti-CCR7 blocking). Error bars represent mean ± SD.we used our coculture model (Figures 1B and 1C) to in-
vestigate tumor cell chemoinvasion, or chemotaxis
through a 3D matrix, toward LECs under static conditions
using primary human dermal LECs (Figure 1D). No LEC
morphogenesis was observed in this model, nor was
any LEC-induced morphogenesis of tumor cells. First,
we saw that MCF10A cells weakly migrated toward
LECs, and that this migration was CCR7 independent,
since neutralizing antibodies against CCR7 and CCL21
did not alter migration (Figure 4). MCF7 cells were also
weakly chemotactic toward LECs, but this was CCR7
dependent, since CCR7/CCL21 blocking reduced che-
motaxis toward LECs to basal levels. The similarity of re-
sponses observed between these two cell types, despite
their differences in chemokine secretion, can be recon-
ciled by comparing their CCR7 expression: although
MCF10A cells appear to produce higher levels of CCR7
ligand, they cannot effectively respond due to the limited
CCR7 expression. In contrast, CCR7 expression is high
on MCF7 cells and thus any CCR7 ligand produced
by these cells can efficiently signal. The two invasive
cell lines, ZR75-1 and MDA-MB-435S, both of which ex-
press high levels of CCR7 receptor and ligand, showed
strong CCR7-dependent chemotaxis toward LECs. These
results demonstrate that LECs chemoattract tumor cells
through a 3D matrix via CCR7 signals, and that more
invasive cells chemotact more strongly toward LECs
than nonexpressing cells, at least for the cell lines tested
here.530 Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc.Autologous Chemotaxis of Tumor Cells
by Interstitial Flow
To investigate the effects of IF on autologous chemotaxis
of tumor cells, we introduced slow flow of 0.2 mm/s, which
is within measured in vivo values (Chary and Jain, 1989;
Dafni et al., 2002), through the 3D cell-Matrigel construct
in the absence of LECs. Strikingly, this slow flow drove
similar chemotactic responses by the tumor cells as did
the LECs under static conditions (Figure 5). Flow also
enhanced the migration of nontumorigenic MCF10A cells
by a small but significant degree, but this enhancement
was not affected by blocking CCR7 signaling (Figure 5).
In contrast, the three tumor cell lines displayed marked
increases in migration in the flow direction that could be
inhibited by CCR7 blocking (Figure 5), indicating that the
flow-enhanced migration was a CCR7-mediated chemo-
tactic phenomenon, yet with no exogenous CCR7 ligands
or LECs to signal. Furthermore, their response was corre-
lated with invasion (at least in the cell lines tested): ZR75-1
and MDA cells displayed the strongest ‘‘autologous
chemotaxis’’ in response to IF. These results clearly dem-
onstrate that autologous chemotaxis toward gradients of
CCR7 ligand occurred in these tumor cells under IF.
Interestingly, the migration in response to flow when
CCR7 signaling was blocked was roughly equal in all
four cell lines, despite their varying responses to flow.
This suggested that flow had a small additional CCR7-
independent effect. It is probable that this increase was
primarily a consequence of directed proteolysis, as the
Cancer Cell
Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 5. Autologous Tumor Cell Chemotaxis by Interstitial Flow Is CCR7 Dependent
Autologous chemotaxis of each cell type, cultured without LECs, in the direction of 0.2 mm/s interstitial flow, with and without CCR7-blocking antibody
cocktail as compared to static conditions. In all cases, CCR7 blocking did not significantly affect baseline (static) migration rates. The 3D migration
of MCF10A cells, which showed little CCR7 expression, doubled in the presence of flow but was unaffected by CCR7 blocking as expected. MCF7
cells, which showed higher CCR7 expression than MCF10A cells, also responded weakly to IF, but in contrast, this increase was CCR7 dependent.
Migration of both ZR75-1 and MDA-MB-435S cells increased dramatically under 0.2 mm/s interstitial flow, and this increase was reversed by CCR7
blocking (*p < 0.05; **p < 0.01 compared with static conditions; Dp < 0.05; DDp < 0.01 between other groups as indicated). Error bars represent
mean ± SD.pan-MMP inhibitor GM6001 abolished all flow-enhanced
migration (data not shown).
To more directly visualize autologous chemotaxis, we
examined the localization in ZR75-1 cells of (1) the pleck-
strin homology domain of the signaling molecule AKT
(PHAKT) in live cells, using lentiviral transduction of the
PHAKT-eGFP transgene; (2) f-actin in fixed cells; and (3)
RAC in fixed cells. PHAKT, normally localized in the cyto-
plasm, becomes recruited to the plasma membrane as
part of a receptor signaling complex that includes RAC
when, following stimulation, f-actin cytoskeleton reorgani-
zation is required (e.g., during chemotaxis), indicating
polarization, which alludes to subsequent cell movement
(Servant et al., 2000). Using real-time fluorescence mi-
croscopy, we observed polarization responses under
static, flow, and flow + CCR7 neutralization conditions.
In static 3D conditions, cellular PHAKT-eGFP localization
was weak and randomly directed (Figure 6A), while under
IF, localization was visibly enhanced, polarizing in the
general direction of flow (Figure 6B), consistent with the
migration data. Significantly, when these cells were ex-
posed to IF in the presence of blocking antibodies to
CCR7 and CCL21, polarized membrane localization of
PHAKT was inhibited and reflected a similar distribution
of polarization directions as displayed by static cultures
(Figure 6C). As a positive control, we saw biased PHAKT
localization in the direction of an imposed CCL21 gradient
under static conditions (Figure 6J, with a cell in 2Dexposed to the same CCL21 gradient shown in
Figure 6K as a comparison).
It is well established that small GTPases regulate cyto-
skeleton dynamics in response to migratory stimuli; in
particular, Rho GTPases such as RAC mediate f-actin
polymerization at the polarizing cell’s leading edge (as
reviewed in Charest and Firtel, 2007; Fukata et al.,
2003). Consistent with the PHAKT data, we saw that
flow induced preferential actin localization at the leading
edge of the cell (Figure 6E), which was not repeated in
either ‘‘static’’ (Figure 6D) or ‘‘flow + block’’ (Figure 6F)
conditions. Polarized RAC expression was also observed
under the influence of IF (Figure 6H) but not under flow +
block conditions (Figure 6I). Thus, IF mediated not only
preferential migration, but also cell polarization that was
dependent on autocrine CCR7 signaling.
To quantify this polarization effect of IF, each cell was
scored (Figure 6L) and classified as (1) nonpolarized, (2)
polarized with flow direction (region I, 0–60), (3) polarized
orthogonal to the direction of flow (region II, 60–120), or
(4) polarized against flow direction (region III, 120–180).
In all cases—static, flow, flow + block, and static with an
applied CCL21 gradient—more than half of all cells did
not show any polarization. In those cells that did polarize,
no directional biases were seen in static conditions, but
cells under flow displayed a 4-fold increase in directional
bias toward flow that was abolished when CCR7 signals
were blocked (Figure 6M). Hence, under static conditions,Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc. 531
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Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 6. Polarization of Cells in Response to Biophysical and Biochemical Stimuli
(A–C) PHAKT-eGFP localization and polarization within ZR75-1 cells in two representative cells (left and right panels) from 3D static gels (A), 3D gels
under interstitial flow (B), and 3D gels under interstitial flow with CCR7-blocking antibody cocktail (C). Live microscopy demonstrated that flow was
able to induce directional polarization that was CCR7 dependent; inhibition of CCR7 signaling prevented polarization responses. Arrows represent
flow direction. Insets indicate examples of quantification for representative cells. (D–F) Staining of fixed samples with phalloidin in two representative
cells (left and right) demonstrates directional reorganization and membrane localization (arrowheads) of the actin cytoskeleton in a flow-dependent (E)
and CCR7-dependent (F) manner. No reorganization was observed in static conditions (D). Arrows represent flow direction. (G and I) Colabeling of
fixed cells following live experiments reveals that membrane localization of the signaling molecule RAC (left panel) coincident with F-actin (right panel)
could only be detected in cells exposed to IF ([H], arrowheads). This was not apparent in static (G) or flow + block (I) situations. Arrow denotes flow
direction. (J and K) Live-imaged PHAKT-eGFP localization and polarization within ZR75-1 cells in two representative images of 3D gels with an
exogenous 1% transcellular CCL21 protein gradient (J), and the same CCL21 gradient in 2D culture (K); for cells in static conditions, one arbitrary
direction was fixed as the reference direction. Insets indicate examples of quantification for representative cells. Scale bars, 50 mm in (A)–(C), (J),
and (K), 25 mm in (D)–(I). (L) Criteria for quantifying polarization responses of cells. Each cell was scored according to its orientation relative to the
direction of flow or imposed CCL21 gradient and assigned as not polarized or polarized in one of three regions (directed parallel [I], orthogonal
[II], or opposite [III] to the direction of flow) as shown. (M) Summary of cell polarization in response to flow. In all cases, roughly half or more of analyzed
cells were not polarized. Among those cells that did polarize, PHAKT-eGFP localization was directionally unbiased in static and flow + block condi-
tions, in contrast to conditions of flow and exogenous CCL21 gradient, where cells preferentially polarized with rather than against the direction of flow
or exogenous chemotactic gradient.or when signaling was prevented, there were effectively no
biasing factors and cells polarized randomly or not at all. In
contrast, when exposed to IF, cells polarized in the direc-
tion of flow similarly as those exposed to an applied
CCL21 gradient of 5.5 mg/ml/mm. This further supported
the notion of IF-induced, CCR7-dependent autologous
chemotaxis.
Combined Effects of Flow and LECs Lead
to Amplified Response
Finally, using the most invasive cell line, MDA-MB-435S,
we examined the combined response of tumor cells to
LECs and IF (Figure 1A), as would occur in vivo. As ex-
pected, the two effects combined to drive even stronger
532 Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc.chemotaxis in the direction of LECs than did either factor
alone (Figure 7A). Combined, flow-enhanced migration of
tumor cells toward LECs was roughly three times that of
their migration toward either cue alone. When CCR7 sig-
naling was blocked, the percent migration was not signif-
icantly different than either that seen with flow alone with
blocking, or that with LECs alone with blocking, indicating
that the combined synergistic effect was also CCR7
mediated.
Computational Modeling of the Tumor-Lymphatic
Microenvironment
To explain the autologous chemotactic effects observed,
we hypothesized that IF could bias the distribution of
Cancer Cell
Autologous Chemotaxis of Tumor Cells to LymphaticsFigure 7. Combined Effects and Compu-
tational Modeling
(A) Summary of in vitro migration experiments
comparing the individual and combined effects
of LECs, interstitial flow, and CCR7 blocking on
transmembrane migration of MDA-MB-435S
cells demonstrate that both autocrine and
paracrine signaling are CCR7 dependent, and
that the combined effects of flow and LECs
are stronger than either effect alone.
(B) Computed transcellular chemokine and
protease gradients perceived by cells are con-
sistent with in vitro migration trends: first, both
LECs (in static conditions) and interstitial flow
(in LEC-free conditions) impose similar CCR7
ligand gradients, just as they produced similar
migratory responses in tumor cells. Second,
the combined gradient is nearly three times
larger than that for LECs or interstitial flow
alone. Gray bars represent transcellular
protease gradients that may potentially cause
a secondary effect of directed proteolysis
that could explain above-baseline migration
levels that persist in flow conditions even with
the use of blocking antibodies.
(C) Graphical representation of CCL21/19
gradients around a tumor cell embedded in
3D matrix corresponding to (left to right) static
culture with LECs, interstitial flow without
LECs, and interstitial flow with LECs. Red-
blue color gradient indicates maximal-to-zero
concentration, and arrow indicates direction
of flow.
(D) Numerical results tabulated for direct com-
parison. Protease concentration differences
are normalized against the value for the static
case.
Error bars represent mean ± SD.Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc. 533
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Autologous Chemotaxis of Tumor Cells to LymphaticsCCL21 and CCL19 released by the tumor cell and,
together with similar biasing of cell-released proteases
that could further liberate bound chemokines from the
matrix, create pericellular gradients of autocrine CCR7
ligands that increase in the downstream direction to drive
chemotaxis. This was based on recent findings that slow
flow could synergize with matrix-bound vascular endothe-
lial growth factor (VEGF) to drive capillary morphogenesis
in vitro (Helm et al., 2005), and on recent computational
modeling describing how such gradients might be formed
(Fleury et al., 2006). It is important to note that, under such
conditions, diffusion still dominates the overall transport
problem—the Peclet number, which describes the relative
contribution of convection compared to diffusion in the
overall transport, is only 0.02—but the contribution of
convective transport is sufficient to skew the diffusion
gradient downstream and actually create a difference in
concentration between upstream and downstream sides
of the cell. In other words, while diffusion determines the
overall magnitude of the chemokine gradient away from
the cell, convection changes its shape, and thus gradient,
relative to the cell.
We modeled the specific case of CCR7 ligands (CCL19
and 21) secreted by a cell into the pericellular matrix under
0.2 mm/s flow. First, the ligands were assumed to be
secreted uniformly from a 20 mm cell at constant flux
and transported away from the cell by diffusion and
convection, and CCL21 was also subject to matrix binding
according to its equilibrium-binding kinetics with heparan
sulfate (Uchimura et al., 2006). The same cell was
also considered to secrete matrix-degrading enzymes
(MMPs, sulfatases, etc.) that were capable of further liber-
ating ECM-bound CCL21, so that the final soluble CCL21/
19 profile was a combination of cell-secreted and ECM-
released ligands. Only this soluble fraction of ligand was
assumed to bind CCR7. This differs from previously pre-
sented cases, where ligand was initially present uniformly
bound to the matrix, or where ligand was secreted in a
pro-form and only active upon protease cleavage (Fleury
et al., 2006; Helm et al., 2005). We modeled all experimen-
tal cases, comparing autocrine, paracrine, and combined
signaling under conditions of static versus flow, and with
and without CCR7 blocking.
Chemotaxis in 3D is the result of a combination of
signaling inputs to the cell, matrix compliance, and active
cellular response such as the engagement of cell motility
machinery. The computational model addressed only
the signaling input to the cell with the implicit assumption
that the overall chemotactic response would be propor-
tional to this stimulus (Janetopoulos et al., 2004). The pre-
dicted chemokine gradients were indeed qualitatively
consistent with our experimental migration results. First,
we predicted that paracrine effects of LEC-secreted
CCL21/19 (under static conditions) induced a transcellular
ligand gradient of 1.4% across the tumor cell surface
(Figure 7B). During the transient portion of the gradient
formation, this value varies with time and location through
the 500 mm thick matrix; we chose to model a reference
cell 150 mm from the bottom boundary of the gel, which
534 Cancer Cell 11, 526–538, June 2007 ª2007 Elsevier Inc.is within the limits of where the cells that transmigrate in
15 hr would be expected to be located within the gel
originally.
We then modeled autocrine effects (no LECs) and saw
that interstitial flow of 0.2 mm/s can bias the transcellular
gradient of both CCL21/19 and cell-secreted proteases
in the direction of flow (Figure 7B). These data correspond
qualitatively with the in vitro results (Figures 7A and 7D).
Specifically, we found that the calculated CCL21/19 trans-
cellular gradient, which would act as the chemotactic
stimulus for a cell, was similar between a tumor cell alone
under flow (1.2%) and the static case when LECs are pres-
ent (1.4%), which was consistent with the experimental
data demonstrating that these two conditions had each in-
duced similar migration responses (1.3% and 1.1% flow
alone and LECs alone, respectively).
When both autocrine and paracrine effects were com-
bined with flow effects, the transcellular gradient was
increased approximately 3-fold, which was consistent
with the experimental results showing that the percentage
of transmigrated cells was also roughly tripled compared
to either condition alone. While we hypothesize that
migration is principally driven by biased CCL21 gradients,
a secondary mechanism may also be present: proteases
secreted by tumor cells are also subject to the biasing
effects of interstitial flow (Figures 7B and 7D), which could
lead to increased migration in the direction of flow due to
directed proteolysis. While CCR7 blocking should abolish
the chemotactic mechanism, it should not affect directed
proteolysis (Figure 7B). Consistent with this notion, in vitro
migration experiments show that, while CCR7 blocking
inhibits flow-enhanced migration, there still remain some
residual enhancement of migration (although not statisti-
cally significant in any cell type) compared to that in static
controls (Figure 7A).
Thus, our experimental results demonstrate that (1)
slow IF can induce autologous chemotaxis of tumor cells
in the direction of flow; (2) slow IF steepens the gradient of
CCR7 ligand secreted by LECs to enhance paracrine
chemotaxis of tumor cells toward LECs; and (3) when IF
is directed toward CCL21-secreting LECs, i.e., when a
lymphatic is functional and draining fluid, the combination
of effects leads to a greatly enhanced chemotactic trans-
cellular gradient to further drive tumor cells toward the
lymphatic.
DISCUSSION
This study highlights the importance and relevance of the
biophysical microenvironment to lymphatic metastasis
and introduces a mechanism that we term autologous
chemotaxis whereby autocrine chemokine secretion
directs tumor cells to chemotact in the direction of flow,
i.e., toward draining lymphatics. It provides mechanistic
insight into why CCR7 expression correlates with lymph
node metastasis in human cancers (Gunther et al., 2005;
Heresi et al., 2005; Shields et al., 2007; Takeuchi et al.,
2004; Wang et al., 2005; Wiley et al., 2001) and introduces
the concept that tumor invasiveness toward draining
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secretion of CCR7 ligands. Furthermore, when the tumor
cell comes in close proximity to a lymphatic, which can
also secrete CCR7 ligand, the tumor-derived CCL21/19
gradient can add to the lymphatic-secreted CCL21 to
further augment the chemotactic response of tumor cells
toward functional draining lymphatics. Interestingly, while
IF decreases the transport distance of CCL21 secreted by
the lymphatics, it actually increases the transcellular gra-
dient across a nearby tumor cell (within its broadcast
distance), since the concentration gradient becomes
steeper. This is important because chemotacting cells
respond to a concentration difference rather than an
absolute amount (Zigmond, 1977; Janetopoulos et al.,
2004).
Because IF is always directed from the tumor toward
the lymphatic, and because chemokine signaling appears
to play a critical role in lymphatic homing of tumor cells, an
experimental model system to study tumor-lymphatic
interactions should both include appropriate levels of in-
terstitial flow and allow for chemokine signaling to occur.
Experimental models of tumor-lymphatic interactions
have been mostly limited to human tumor xenografts in
mice, where relative migration is difficult to assess, and
where chemokine signaling varies due to compromised
immune systems and potential incompatibilities between
some rodent and human cytokines. Standard in vitro
chemotaxis assays often do not include biophysical
factors, like ECM and IF, which could strongly affect trans-
port and distribution of secreted chemokines and thus
relevant cell-cell signaling events. Tissue-engineered 3D
models have advantages over both in vivo and traditional
in vitro models for examining interactions between human
cells in an environment that recapitulates some biophysi-
cal features of the natural in vivo situation (Griffith and
Swartz, 2006).
Using a 3D in vitro coculture model, we demonstrate
how biophysical factors of the tumor-lymphatic microen-
vironment favor tumor cell migration toward functional
lymphatics. We saw that melanoma and breast tumor cells
secrete CCL21 and CCL19, and that they do so to a much
higher degree when maintained within a 3D matrix than in
2D. Furthermore, these cells are responsive to CCR7
ligand and can chemotact up an imposed CCL21 gradient
as well as toward LECs in a CCR7-dependent manner.
Strikingly, physiological levels of IF significantly enhanced
tumor migration in the direction of flow, with and without
LECs. These responses could be reversed by blocking
CCR7 signals, clearly illustrating that flow-enhanced mi-
gration is a phenomenon of CCR7-dependent chemotaxis.
Computational simulation of CCL21/19 transport under
this flow estimated a transcellular CCL21/19 gradient to
be 1.2% without LECs and 4.1% with LECs. Although
the limits for tumor cell sensing of CCL21/19 gradients
are not known, it has been shown that neutrophils can
directionally sense as little as 1% differences in transcellu-
lar concentration of chemoattractant (Zigmond, 1977),
and similarly, small morphogen gradients are known to
act as positional cues for cells in many developing tissues(Ashe and Briscoe, 2006; Yucel and Small, 2006). Further-
more, we demonstrated, using the PHAKT-eGFP cell
polarization marker as well as by staining for f-actin and
RAC, that such imposed biophysical cues alone could
initiate cellular signaling events needed for actin reorgani-
zation and cell polarization. Thus, it is highly probable that
small transcellular chemokine gradients formed by flow
are responsible for stimulating chemotaxis of tumor cells
in the direction of flow.
In conclusion, we have demonstrated the importance of
the tumor-ECM-lymphatic microenvironment for lym-
phatic metastasis and identified a mechanism for tumor
cell homing to lymphatics that is consistent with human
cancer data correlating CCR7 expression with lymph
node metastasis. In addition to introducing autologous
chemotaxis, this is, to our knowledge, the first demonstra-
tion that tumor cells can respond to autocrine CCR7 li-
gands, and also that physiological levels of IF can enhance
tumor cell migration in the direction of flow. These results
help elucidate fundamental mechanisms of tumor cell in-
vasion of lymphatics and may also be relevant to under-
standing how leukocytes home to lymphatics.
EXPERIMENTAL PROCEDURES
Antibodies, Flow Cytometry, and Immunofluorescence
Neutralizing antibodies against human CCL21 (AF366) and CCR7
(MAB197) were purchased from R&D Systems (Minneapolis, MN)
and used at 4 mg/ml and 5 mg/ml, respectively. Antibodies against hu-
man podoplanin (gp36; 10 mg/ml, Cell Sciences, Inc., Canton, MA),
CD31 (10 mg/ml, BD Pharmingen, San Diego, CA), LYVE-1 (15 mg/ml,
RELIATech, Braunschweig, Germany), and Prox1 (5 mg/ml, RELIA-
Tech) were used with mouse IgG as a control (10 mg/ml, Sigma). Alexa
Fluor 488-labeled IgGs (Molecular Probes, Carlsbad, CA) were used
for detection, and DAPI (Vector Laboratories, Burlingame, CA) was
used for counterstaining nuclei. Cytoskeleton polarization machinery
was stained for RAC (10 mg/ml, AbCAM) and f-actin (AF488 Phalloidin,
Molecular Probes). Immunostaining was performed for CCL21 (15mg/ml,
AF366), CCL19 (8 mg/ml, AF361), and CCR7 (25mg/ml, MAB197) (all R&D
Systems).
Sections from archived malignant human breast tissue samples
(kind gift from Dr. Cathrin Brisken, obtained under the authority of
the Ethics Committee of the Centre Hospitalier Universitaire Vaudois
with patient consent) and normal breast tissue (ab4324, Abcam)
were subjected to standard immunohistochemistry for CCR7 (8 mg/ml)
and CCL21 (8 mg/ml) and counterstained with hematoxylin.
Cell Culture
MCF10A, MCF7, ZR75-1, and MDA-MB-435S cells (all from ATCC/
LGC Promochem, Middlesex, UK) were maintained in 1:1 DMEM:F12
Hams (with 0.01mg/ml bovine insulin,0.5mg/ml hydrocortisone,20ng/ml
EGF, 5% FBS, and 1% penicillin-streptomycin), a-MEM (with 2 mM
L-glutamine, 1 mM sodium pyruvate, 0.01 mg/ml bovine insulin, 10%
FBS, and 1% penicillin-streptomycin), RPMI 1640 (with 2.5 g/l
D-glucose, 1 mM sodium pyruvate, 10 mM HEPES, 10% FBS, and
1% penicillin-streptomycin), and DMEM with 10% FBS, respectively.
Human dermal LECs were isolated from neonatal foreskin and cultured
as previously described (Podgrabinska et al., 2002) and immuno-
stained for typical LEC markers (Figure 1D).
Reverse Transcriptase PCR
Total RNA was isolated with RNAqueous extraction kit (cat number
1912, Ambion, Austin, TX) according to the manufacturer’s guide-
lines. CCR7 fragments were amplified using forward primer
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ACTGCTGCTCCTCTGG-50 to yield a product of 341 bp. A human P0
control (data not shown) was included using forward primer 50-GCCA
CGCTGCTGAACATGCTCAAC-30 and reverse primer 30-CCGACTCC
TCCGACTCTTCCTTGG-50 to yield a product of 409 bp.
Static Migration Assay
Experiments were performed with 12 mm diameter, 8 mm pore cell cul-
ture inserts (Millipore, Billerica, MA) in a modified Boyden chamber
assay. For chemotactic gradient studies, 50,000 tumor cells were
seeded in 150 ml (1 mm thick) Matrigel (4.65 mg/ml, BD Biosciences,
San Jose, CA). Basal medium was placed in the top chamber, while
the bottom contained basal medium either alone, with 350 ng/ml
CCL21 protein, or with both CCL21 protein and a cocktail of anti-
CCR7 and anti-CCL21 blocking antibodies (in the latter case,
antibodies were also included in the top chamber). After 15 hr in
a 37C/5% CO2 incubator, Matrigel containing nonmigrated cells
was removed and the inserts were fixed in chilled methanol. The mem-
brane was removed and mounted with Vectashield containing DAPI
(Vector), and the number of migrated cells was counted.
Coculture Migration Assay
For assessing chemotaxis of tumor cells toward LECs, a coculture as-
say, modified from the above setup, was used. LECs were seeded
onto the collagen-coated underside of the chamber at 100,000 cells/
well and cultured to confluence (3 days). The migration assay was
then prepared as described above but modified to incorporate
50,000 tumor cells seeded within 50 ml Matrigel.
Migration under Flow
The above setup was modified to examine the effects of physiological
flow on tumor cell migration, either with or without LECs on the under-
side of the chamber as described. After the Matrigel was cast and
allowed to set, a pressure head of 1 cm water was established that led
to an average velocity of 0.2 mm/s through the cell/gel compartment
(flow rate determined in separate experiments both by direct measure-
ments and using measured permeability; data not shown). Migration in
the presence of basal media, alone or with anti-CCR7 and anti-CCL21
blocking antibodies, and with or without flow, was assessed.
Western Blot Analysis
CCR7 expression was analyzed by Western blot using 0.5 mg/ml
mouse anti-CCR7 (R&D Systems), HRP-conjugated goat anti-mouse
IgG (BioRad), and a Western Pico ECL substrate kit (Pierce, Rockford,
IL). Sample loads were normalized to cell number in three separate
experiments.
ELISA
CCL19 and CCL21 protein secretion was quantified using ELISA kits
(R&D) from cells maintained in both 2D and 3D culture conditions in
basal media. For 2D samples, conditioned media were collected after
24 hr culture. 3D samples were analyzed following culture of 450,000
cells per well (in 24-well plates) within 300 ml of Growth Factor Re-
duced Matrigel in basal media for 24 hr. To account for matrix-bound
ligands, three compartments were analyzed by ELISA: medium, ma-
trix protein (by digestion with Cell Recovery Solution [BD Biosciences,
San Jose, CA]), and cells (by lysis using standard RIPA buffer proto-
cols [Sigma]).
Computation of Extracellular CCL21 Distribution
Pericellular CCL21/19 gradients were computed using a 3D model
according to the following:
dCi
dt
+ v$VCi =DiV
2Ci +Ri
where Ci is concentration of species i, t is time, v is velocity vector, Di is
the diffusion coefficient, and Ri is the rate of reaction (disappearance
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release from the matrix). The cell was modeled as a 20 mm diameter
sphere embedded 150 mm from the bottom surface of a 500 mm thick
porous ECM (Matrigel) with 3 mm of medium atop the matrix. In simu-
lations involving LECs, the cells were modeled on the bottom of the
ECM layer with a cell density obtained using micrographs of in vitro
preparations. The Brinkman equation was used to calculate the velocity
profile through the porous ECM around the cell using a value for perme-
ability K = 1012 cm2 (calculated from our experimental data) and aver-
age v = 0.2 mm/s. Four species i were modeled: P, the cell-released
protease; CCL21, the cell-released CCL21; CCL19, the cell-released
CCL19; and HS-CCL21, the matrix-bound CCL21. Constant flux
boundary conditions were assumed for both P and CCL21/19 at cell
surfaces, with CCL21/19 fluxes measured experimentally (Figure 3),
along with zero flux inlet boundary conditions. The diffusion coefficients
were assumed to be 140 mm2/s forCCL21/19 and 80 mm2/s forP (Fleury
et al., 2006). The modeled species were subjected to the following
binding and release kinetics:
CCL21+HS4
kon
koff
HS CCL21
HS CCL21+P/krel CCL21+HS+P
where HS = heparin sulfate binding sites; HS-CCL21 = matrix-bound
CCL21; and kon, koff, and krel are rate constants for the reactions
shown. kon and koff were assumed to be 9.3 3 10
4 M1s1 and 1.2 3
104s1, respectively, based on our own measurements (data not
shown), and krel was assumed to be 1 3 10
5 M1s1. (This value was
chosen arbitrarily to make the release term on the same order of mag-
nitude as the ‘‘on’’ rate, but parametric variation of krel revealed that,
while its value affected absolute CCL21 concentrations, it had no
effect on the percent transcellular gradients calculated.)HSwas calcu-
lated to be 1.2 mM assuming 2% proteoglycan (perlecan) content in
Matrigel and 12 binding sites per perlecan molecule.
The corresponding rate equations were as follows:
RCCL21 =  konCCCL21CHS + koffCHSCCL21 + krelCHSCCL21CP
RHSCCL21 = konCCCL21CHS  koffCHSCCL21  krelCHSCCL21CP =  RCCL21
where R refers to the overall rate of production and C refers to the
concentration of each of the components defined above. CHS was
considered to be much larger than CCCL based on the calculated
number of binding sites in the Matrigel relative to the total CCR7 ligand
concentration (Figure 3) and therefore was treated as a constant.
CCL19 was assumed not to interact with the matrix and was therefore
not subject to a reaction term.
Mass balances for free ligand, bound ligand, and protease were
solved simultaneously in a transient analysis to estimate the combined
CCR7 ligand gradients that would be established after 50,000 s,
matching the experimental time frame. The calculations were
performed using COMSOL Multiphysics modeling software (Berne,
Switzerland) on a personal computer.
PHAKT-eGFP Polarization Assay
The fluorescent probe used to determine spatial distribution of inter-
mediate intracellular signals between activation of chemotactic recep-
tors and actin polymerization, the PHAKT-eGFP construct (Servant
et al., 2000), was a kind gift from Tamas Balla. A cassette containing
the PHAKT-eGFP, an EcoRI-HincII fragment, was blunt-end ligated
into the lentivirus backbone pRRLsincPPT-hPGK-mcs-WPRE (a kind
gift from Didier Trono) and expanded in competent E. coli. Clone
DNAs from antibiotic-resistant colonies were purified and analyzed
for the correct recombination event. Lentiviral vectors were produced
via transfection of HEK293T cells with the PHAKT-eGFP transfer
construct, pCMVR8.74 packaging plasmid, and pMD2.G envelope
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virus was concentrated by ultracentrifugation in 20% saccarose solu-
tion. ZR75-1 cells were infected with the lentivirus in 24-well plates and
checked for stable expression of PHAKT-eGFP.
PHAKT-eGFP-ZR75-1 cells were seeded at 106 cells/ml within a
matrix (3:1 collagen:Matrigel) and placed within a radial flow chamber
as described (Ng et al., 2005). Slow IF, via a constant pressure head
(leading to an average flow velocity of 0.2 mm/s near the outer
edge of the chamber, where images were taken) was applied to the
system for 7 hr (maintained at 37C/5% CO2 on the microscope stage),
during which time live cells were visualized and photographed on
a Zeiss fluorescence microscope (Axiovert 200M). Gels were then
fixed and stained for cytoskeleton machinery proteins (as described
earlier) and visualized on a Zeiss LSM Meta 500 inverted confocal
microscope.
For cells exposed to an exogenous CCL21 gradient in 2D or 3D,
PHAKT-eGFP-ZR75-1 cells were seeded into an IBIDI mVI culture slide
(Ibidi, Munich, Germany) either in basal medium or in Matrigel and al-
lowed to establish overnight. CCL21 (350 ng/ml) was added to the
inlet, and basal medium was added to the outlet, creating a 1 cm dis-
tance over which a gradient could form. Cells were maintained in this
gradient for 20 min or 6 hr (2D and 3D, respectively), and then cells
within 200 mm of the CCL21 depot were visualized with a Zeiss fluores-
cence microscope.
Statistical Analyses
To test for statistical significance between experimental groups,
Kruskal-Wallis and Mann-Whitney U tests were performed. Statisti-
cal significance was assumed where p < 0.05. All bar graphs show
mean ± SD.
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